Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Cabinet OKs Extra Budget, 3.5 Billion Yen Allocated for IFN-Free Treatment
January 13, 2015
- Panel Agrees to Add Hepatitis B Vaccines to Public Immunization Program
January 13, 2015
- MHLW Calls for Revision of Package Inserts for SGLT-2 Inhibitors
January 13, 2015
- FY2015 Budget to Earmark 47 Billion Yen to Promote Healthcare R&D
January 9, 2015
- PAFSC 2nd Committee to Discuss Eisai’s Anticancer Agent on Jan. 21
January 9, 2015
- 30% R&D Tax Deduction Cap Could Be Secured with Open Innovation Tax Break: Economic Affairs Division
January 8, 2015
- 2015 to Be “Starting Year for Major Reform” of Healthcare and Nursing Insurance Systems: Health Minister
January 8, 2015
- Public Trust Indispensable for Industry Development: Mr Futagawa of Health Policy Bureau
January 7, 2015
- Pharmaceutical and Food Safety Bureau to Promote Prescription-to-OTC Switches Based on Industry Opinions
January 6, 2015
- MHLW OKs 31 Products Including Takeda’s Vonoprazan
January 5, 2015
- Ruling Parties Settle on 25%-Plus-5% Cap for R&D Tax Credit
January 5, 2015
- Health Minister Shiozaki Reappointed
December 25, 2014
- LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
- Integrated Clinical and Epidemiological Research Ethical Guidelines to Take Effect April: MHLW
December 25, 2014
- Deliberations on Specific Cases of Cost-Effective Assessments to Be Closed to the Public: Chuikyo
December 25, 2014
- Investigation Finds No Intentional Data Falsification from J-ADNI Study
December 25, 2014
- MHLW Orders Revision of Package Insert for Jevtana
December 24, 2014
- Novartis Pharma Should Take Thorough Measures to Prevent Worker Involvement in IITs: Health Minister
December 22, 2014
- New “Compassionate Use” System to Be Introduced in FY2015; Will Apply to Industry-Sponsored Trials as well as IITs
December 22, 2014
- Orphan Designation to Be Expanded to Include Intractable Diseases Affecting More than 50,000 Patients
December 22, 2014
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…